semaglutide impulse control New insights into weight management for patients on antipsychotics! A recent study led by a team of researchers from EGDRC, Jithin Sam Varghese, David R. Goldsmith, Robert O. Cotes, @@mohammedkali_global, and Francisco Ozempic may be a secret

Prospective patients should not interpret the availability of this format as equivalence to any FDA-approved injectable product

Study period 1/1/2017 to 7/1/2025 Study population: inclusion Patients with A GLP-1 prescription for at least 90 days At least five pounds of weight loss while on the GLP-1 A weight reading between 30 days prior through 3 days after starting the GLP-1 A weight reading within 30 days of stopping the GLP-1 At least one weight reading 1 to 24 months following end of the GLP-1 Study population: exclusion Thyroid conditions (ever): ICD-10-CM E03*or E05* Eating disorders (ever): ICD-10-CM F50* Pregnancy within a year before GLP-1 start through GLP-1 stop Censoring Other weight loss medication or restart of GLP-1 Amputation Bariatric surgery Pregnancy that started in period after GLP-1 was stopped Outcomes Percent of weight change relative to initial weight loss after end of GLP-1 treatment GLP-1 A medication with a simple generic of semaglutide, liraglutide, or tirzepatide

A study conducted by Mali et al

2024 data also confirms that semaglutide users choose salads over fast food by 68% more often by week 16

R., Scolyer, R

The continued exploration of semaglutides potential in blood sugar control and weight management reflects a growing interest in comprehensive solutions that address multiple aspects of health